CBG (Cannabigerol).

Cannabigerolic acid is the branch point the plant converts into cannabidiolic acid and the other major cannabinoids, so CBG is the parent of CBD rather than a parallel molecule. High-CBG chemotypes are ones where that conversion is limited.

Both sit on the cannabigerolic acid pathway, with cannabinol appearing later as an oxidation product of the tetrahydro form. Their relative amounts describe the chemotype and the age of the material.

Cannabigerol is the parent phytocannabinoid of the class, so a generic cannabinoid input and a CBG input contribute to one total. Reading them separately double counts.

Cannabigerol is lipophilic and reaches circulation far better from a fat vehicle that supports micelle formation. Medium chain triglyceride is the standard base for oral CBG preparations.

CBG is cleared by CYP450 oxidation and glucuronidation, both of which piperine slows. The result is higher exposure from an unchanged dose.

CBG is highly lipophilic and dissolves poorly in gut water, so it depends on a lipid or emulsifier phase to form absorbable mixed micelles. Phospholipids from lecithin provide that emulsifier function and are the basis of liposomal and nanoemulsion hemp preparations. The role is delivery, not added activity.

Phosphatidylcholine forms bilayer vesicles that carry lipophilic molecules such as CBG into a dispersible form. The same chemistry underlies liposomal delivery of other fat-soluble actives. It changes how much of the molecule presents to the intestinal wall rather than what the molecule does once absorbed.

Cannabinoid absorption rises sharply when taken with a fat-containing meal, because long-chain triglycerides trigger bile release and route part of the dose through intestinal lymphatics. A long-chain omega-3 oil supplies exactly that fat context. The consequence is higher and more variable systemic exposure, which is a dosing consideration as much as a benefit.

CBG is cleared largely by CYP2C9 and CYP3A4, and quercetin inhibits several P450 isoforms in vitro and at high supplemental intakes. Taken together, clearance of the cannabinoid could slow and exposure rise. The direction is predictable from enzyme biochemistry, but the size of the shift in people has not been measured.

Long-chain triglyceride oils such as olive oil are used as tincture carriers because CBG stays dissolved in them and is delivered with a fat load. Compared with medium-chain triglycerides, long-chain oils favour more lymphatic routing and slower onset. The choice of carrier changes the exposure curve, not the molecule.